Gemvax & KAEL said Wednesday that the European Association of Urology (EAU) has selected a research paper on GV1001, its treatment for benign prostatic hyperplasia (BPH), as one of the outstanding papers.
EAU, along with the American Urology Association (AUA), is the most authoritative institution in the field of urology.
|Professor Lee Kyung-sup|
Professor Lee Kyung-sup of the department of urology at Dongguk University Gyeongju Hospital presented the paper at the 2018 EAU conference held in Copenhagen last Friday. Lee was the lead researcher in the randomized, placebo-controlled, single-blind, parallel design and multicenter-controlled clinical trial, which ended in June last year.
“The efficacy of GV1001 in clinical trials has shown the potential to overcome the shortcomings of existing therapies,” Professor Lee said. “Also, urologists from all over the world showed great interest and asked about the possibility of planning or participating in the phase 3 trials.”
Such interest among clinicians confirms that GV1001 will become a new breakthrough drug in treating BPH, Lee added.
Other participants backed Lee’s statement and portrayed interest in the drug.
“The development of a new drug for BPH, one of the diseases that affect the quality of life for the elderly, is currently at a standstill,” said Professor Shigeo Horie, former president of the Asia Pacific Prostate Society. “If GV1001 completes phase III clinical trials, the clinical significance of GV1001 in the Japanese market, which has the fastest-growing elderly population in the world, will be immense.”
The company also showed confidence in its drug candidate.
“Awards from prestigious conferences prove that numerous urologists have objectively verified the efficacy of the drug,” GemVax & KAEL CEO Song Hyoung-gon said. “We are preparing for global and domestic phase 3 clinical trial smoothly.”
<© Korea Biomedical Review, All rights reserved.>